RE: 10p IPO, big Rerate coming20 Feb 2022 19:39
Commenting, Dr Hui Wu, CEO and Founder of
iCCAMT said:
"This agreement represents a significant opportunity to
bring early and cost-etfective cancer detection to the
people of China. It is estimated that about 95.8 million
people in China have a high risk of lung cancer and if
screening was performed every three years, thennore
than 30 million tests per year would be required. JAt a
target price of about GBP100 per test, the total
available market for tests based on the CIZIB
biomarker would be GBP3 billion. (Frost & Sullivan
estimates the market size in China is USS5.7 billion)
We have already secured strong interest from our
nationwide network of national clinical centers and key
opinion leaders because of the promising results using
the CIZIB biomarker for lung cancer early detection in
the UK and one our first tasks is to commence pilot
studies at the Cancer Hospital, Chinese Academy of
Medical Sciences, National Cancer Centre, and Beijing
Cancer Hospital, aftiliated with Peking University."